Date: Thursday 2nd May 2019 – Friday 3rd May 2019Venue: Victoria and Albert Hotel, Water St, Manchester, M3 4JQAccommodation: Victoria and Albert Hotel, Water St, Manchester , M3 4JQ (accommodation is bookable separately when you complete the online booking form) Organised by: Professor Jo Neill and Dr Richard DrakeProgrammeThursday 2 May10:00–10:30 Arrival, Registration and Coffee10:30–10:35 IntroductionProfessor Jo Neill (Manchester) 10:35–11:10 Causes of schizophrenia: Introduction to current thinkingProfessor Shôn Lewis (Manchester) 11:10–12:00 Pharmacology of antipsychotic medicationDr Rachel Upthegrove (Birmingham) 12:00–12:10 Q&A session12:10–12:45 New trial data and clinical guidelinesProfessor Shôn Lewis 12:45–12:55 Q&A session13:00–13:45 Lunch in the Restaurant13:45–14:35 Recent developments in the psychopharmacological understanding of schizophreniaProfessor Bill Deakin (Manchester) 14:35–14:50 Q&A session14:50–15:20 Pharmacogenomics: impact on efficacy, side effects and adverse drug reactions (& drug interactions)Professor Jo Neill 15:20–15:30 Q&A session15:30–16:00 Refreshments and delegates split into 3 groups16:00–17:30 Group Work – Split into three groupsGroup A: Treatment ProblemsDr Richard Drake (Manchester)Group B: Treatment ProblemsDr Rachel UpthegroveGroup C: Treatment ProblemsProfessor David Owens (Edinburgh) 17:30 End of Thursday SessionsFriday 3 May08:30–08:45 Arrival and Coffee08:45–09:30 Antipsychotics and relapse prevention in schizophreniaProfessor Thomas Barnes (London) 09:30–09:45 Q&A session09:45–10:15 Refreshments10:15–10:55 Adverse effects of antipsychoticsDr Maxine Patel (London) 10:55–11:15 Q&A session11:15–12:15 Pharmacological strategies for treatment-resistant schizophreniaProfessor Thomas Barnes (London) 12:15–12:30 Q&A session12:30–13:20 Lunch in the Restaurant13:20–14:20 EPS UpdateProfessor David Owens (Edinburgh) 14:20–14:35 Q&A session14:35–15:05 Everything you ever wanted to know about first generation antipsychotics but were afraid to askDr Richard Drake (Manchester) 15:05–15:15 Q&A session15:15 Meeting ends. Return of evaluation formsLast edited 2nd November 2018Learning ObjectivesAt the end of this module, the attendees will:Be aware of current theories of the causes and neurochemistry of schizophreniaKnow the pharmacology of conventional and atypical drugsBe aware of the clinical assessment of therapeutic and adverse effectsHave an opinion about relative benefits of conventional and atypical drugsBe updated on guidelines and the social context of drug prescribing in schizophreniaHave had an opportunity to discuss difficult management problems with colleagues and expertsOnline registration facilities will NOT be available for this meeting.This meeting is open only to those who are registered for the BAP Clinical Certificate Course (i.e. committed to attending 3 modules). To register for the Certificate Course, complete this form.This module is eligible for 11 CPD hours which are subject to peer group review.For further details contact Susan Chandler, BAP Executive Officer: